Teva

Teva Pharmaceuticals discovered that some bottles of trazodone 50 mg tablets contain foreign tablets or capsules mixed in with the correct medication. The issue affects one lot (1394026) with an expiration date of February 2028. No injuries have been reported.

Teva Pharmaceuticals is recalling specific lots of Claravis (isotretinoin) 10 mg capsules because they contain higher-than-allowed levels of tretinoin, a related chemical impurity. The affected lots are 100067507 and 100067508, which expire on July 31, 2026. No injuries have been reported so far.

Teva Pharmaceuticals is recalling specific batches of Clonidine Transdermal System patches (0.3 mg/day) because they were manufactured using an unapproved raw material that does not meet quality standards. The affected patches were distributed in the U.S. No injuries have been reported.

Teva Pharmaceuticals is recalling specific lots of Clonidine Transdermal System (0.2 mg/day) patches because they were made with an unapproved raw material that does not meet manufacturing standards. Two lots are affected: 100060002 (expires 07/2026) and 100066802 (expires 05/2027). No injuries have been reported.

Teva Pharmaceuticals is recalling certain Clonidine Transdermal System patches (0.1 mg/day) because they were manufactured using an unapproved raw material that does not meet FDA standards. The affected patches were distributed in the U.S. The company and FDA are working to ensure the product is removed from use.

Teva Pharmaceuticals is recalling certain batches of Isotretinoin 40 mg capsules because some capsules may be too strong (superpotent) or too weak (subpotent). This medication is a prescription acne treatment that requires precise dosing. The affected batches were distributed in Florida, Ohio, Puerto Rico, and Mississippi.

Teva Pharmaceuticals is recalling specific lots of Isotretinoin 30 mg capsules because some capsules may contain too much active ingredient (superpotent) while others may contain too little (subpotent). This inconsistency could affect how well the medication works or increase the risk of side effects.

Teva Pharmaceuticals is recalling specific lots of Octreotide Acetate 30 mg injectable suspension due to quality control problems found at the manufacturer. The FDA identified deficiencies that mean the sterility of these vials cannot be guaranteed. No injuries have been reported.

Teva Pharmaceuticals is recalling specific lots of Octreotide Acetate injectable suspension (20 mg) due to quality control issues at the manufacturing facility in Greece. The FDA found deficiencies that could affect sterility—the assurance that the medication is free from harmful bacteria and other microorganisms.

Teva Pharmaceuticals is recalling specific lots of Octreotide Acetate injectable suspension due to sterility concerns identified at the manufacturing facility. The FDA found quality system deficiencies that could affect the safety of the medication.

Teva Pharmaceuticals is recalling specific lots of metoprolol succinate extended-release 200 mg tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication properly in your body. This could affect how well the blood pressure medication works. No injuries have been reported.

Teva Pharmaceuticals is recalling specific batches of Metoprolol Succinate Extended-Release 100 mg tablets because they may not dissolve properly in the body. This means the medication may not work as intended. The recall affects bottles with lot numbers ending in J251 or J252 and expiration dates of 12/2026.

Teva Pharmaceuticals is recalling certain batches of Metoprolol Succinate Extended-Release 50 mg tablets because they may not dissolve properly in the body, which could affect how well the medication works. The affected bottles have specific lot numbers and an expiration date of January 2027. No injuries have been reported.

Teva Pharmaceuticals is recalling specific lots of Metoprolol Succinate Extended-Release 25 mg tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication properly in your body. This could result in the drug not working as intended. No injuries have been reported.

Defective Container - A defect in the side-seal which allows leakage of product.

Subpotent drug; Clavulanate Potassium component

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.